ArticleFrontiers in oncology2025
Hybrid model for predicting microsatellite instability in colorectal cancer using hematoxylin & eosin-stained images and clinical features.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial Intelligence-Based Prediction of Molecular Alterations in Colorectal Cancer Using Routine H&E Whole-Slide Images.International journal of molecular sciences · 2026Review
- Review
- Multimodal foundation models in colorectal cancer: from prediction to trustworthy clinical insight.Briefings in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microsatellite instability (MSI) is a crucial molecular phenotype in colorectal cancer (CRC), which aids in determining treatment strategies and predicting prognosis. However, existing prediction methods have limitations and are not universally applicable to all patient populations. Consequently, we proposed a hybrid prediction model that integrates pathological and clinical features to predict MSI. Materials and methods: This study encompassed two patient cohorts: The Cancer Genome Atlas cohort (TCGA set, n = 559), which was divided into training and internal validation subsets at a ratio of 7:3, and the Dongyang CRC cohort (Dongyang set, n = 123), serving as an external testing cohort. Two deep learning approaches-semi-supervised and fully-supervised-were employed to extract features from pathological images. Subsequently, the pathomic signatures derived from these approaches were integrated with clinical features to develop a hybrid model. The hybrid model was assessed using an external validation cohort to determine the area under the curve (AUC). Furthermore, to investigate genes associated with MSI, we performed enrichment analysis and constructed a protein-protein interaction (PPI) network using mRNA sequencing data obtained from the TCGA database. Results: The fully-supervised pathological model demonstrated promising performance, achieving an AUC of 0.928 in the internal validation cohort, compared to the semi-supervised pathological model's AUC of 0.786. In the external testing cohort, the model attained an AUC of 0.811. Subsequently, a hybrid model was established, which achieved an AUC of 0.949 in the validation cohort and a robust AUC of 0.862 in the test cohort. Additionally, a nomogram was developed to enhance its clinical applicability. Gene Ontology (GO) analysis identified differentially expressed genes (DEGs) related to MSI status, which were enriched in humoral immune response, among other pathways. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) revealed enrichment in pathways such as rheumatoid arthritis. A PPI network identified key hub genes, including IFNG and CD8A. Conclusion: The fully-supervised model consistently outperformed the semi-supervised model in predicting MSI. Furthermore, the hybrid model, which combines pathological and clinical features, demonstrated strong predictive ability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.